Dermata Therapeutics- Warrants (13/08/2026) Other Current Liabilities

The latest other current liabilities for DRMAW is $730K as of March 2026. That compares with $-1.4M in the prior-year period — up 152.6% year over year. Investors often review this figure alongside Dermata Therapeutics- Warrants (13/08/2026)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, DRMAW's other current liabilities moved from $-1.4M to $730K — a 152.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Dermata Therapeutics- Warrants (13/08/2026)'s operating scale or balance-sheet position.

A other current liabilities figure of $730K for DRMAW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting DRMAW's other current liabilities ($730K), review year-over-year change from $-1.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Dermata Therapeutics- Warrants (13/08/2026)'s other current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.